Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: TLSIW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -41.98% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 1739 | Beta 0.48 | 52 Weeks Range 0.81 - 2.24 | Updated Date 02/26/2025 |
52 Weeks Range 0.81 - 2.24 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -205.46% | Operating Margin (TTM) -95.21% |
Management Effectiveness
Return on Assets (TTM) -92.36% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 19855301 |
Shares Outstanding - | Shares Floating 19855301 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. is a commercial-stage medical device company dedicated to developing innovative technologies to deliver therapeutic agents directly to tumors. It was founded in 2009 and has focused on improving outcomes for patients with liver and pancreatic tumors through targeted drug delivery systems.
Core Business Areas
- Drug Delivery Systems: Develops and commercializes devices for targeted delivery of cancer therapeutics directly to tumors, minimizing systemic exposure.
- Pressure-Enabled Drug Delivery (PEDD): Focuses on improving drug penetration into tumors by using pressure gradients to overcome tumor microenvironment barriers.
Leadership and Structure
TriSalus is led by a management team with expertise in medical device development, commercialization, and oncology. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and clinical affairs.
Top Products and Market Share
Key Offerings
- TriNav Infusion System: A device designed to deliver therapeutics directly to liver tumors using PEDD. Market share is difficult to pinpoint precisely due to the niche market, but TriSalus aims to become a leader in targeted liver cancer therapies. Competitors include companies offering TACE (Transarterial Chemoembolization) and other intra-arterial therapies. Revenue from TriNav is growing.
- NanoKnife System: An ablation technology for solid tumors. TriSalus gained rights to NanoKnife in 2023. Market share in ablation therapy is competitive. Major competitors include Medtronic and Boston Scientific, who also offer Ablation Solutions. Revenue is generated by the consumable probes and devices used by NanoKnife.
Market Dynamics
Industry Overview
The interventional oncology market is growing due to the increasing prevalence of liver and pancreatic cancers and the demand for less invasive treatment options.
Positioning
TriSalus is positioned as an innovator in targeted drug delivery for liver and pancreatic tumors, with a focus on improving treatment efficacy and reducing side effects through its PEDD technology.
Total Addressable Market (TAM)
The TAM for interventional oncology is estimated to be billions of dollars. TriSalus is targeting a portion of this market with its focused therapies.
Upturn SWOT Analysis
Strengths
- Innovative PEDD technology
- Focus on targeted drug delivery
- Experienced management team
- Commercial-stage company
Weaknesses
- Limited market share
- Dependence on key products
- Requires physician training
Opportunities
- Expanding product portfolio
- Partnerships with pharmaceutical companies
- Increasing adoption of interventional oncology procedures
- Global expansion
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- BSX
- MDT
- Varian Medical Systems (now Siemens Healthineers)
Competitive Landscape
TriSalus competes with larger medical device companies in the interventional oncology market. Its competitive advantage lies in its PEDD technology, which aims to improve drug delivery to tumors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: TriSalus has shown significant revenue growth as it has launched new products and expanded its market reach.
Future Projections: Future growth is projected to be strong, driven by continued adoption of its PEDD technology and expansion into new markets.
Recent Initiatives: Recent initiatives include expanding its sales force, developing new clinical data, and pursuing regulatory approvals for new products.
Summary
TriSalus is a medical device company with innovative targeted drug delivery technologies for cancer treatment. Its PEDD technology has shown promise for improved outcomes, but it faces competition from larger companies. The company is focused on expanding its product portfolio and increasing market adoption, but must overcome regulatory and reimbursement challenges to drive growth.
Similar Companies
- BSX
- MDT
- VAR
Sources and Disclaimers
Data Sources:
- Company Website
- Public Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 116 | Website https://trisaluslifesci.com |
Full time employees 116 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.